Last reviewed · How we verify
FOLFOX 1d
FOLFOX 1d is a chemotherapy regimen combining 5-fluorouracil, leucovorin, and oxaliplatin to inhibit DNA synthesis and induce apoptosis in cancer cells.
FOLFOX 1d is a chemotherapy regimen combining 5-fluorouracil, leucovorin, and oxaliplatin to inhibit DNA synthesis and induce apoptosis in cancer cells. Used for Colorectal cancer (likely primary indication based on FOLFOX standard use).
At a glance
| Generic name | FOLFOX 1d |
|---|---|
| Sponsor | Sun Yat-sen University |
| Drug class | Combination chemotherapy regimen |
| Target | Thymidylate synthase (5-FU); DNA (oxaliplatin) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
FOLFOX is a combination chemotherapy regimen where 5-fluorouracil (5-FU) inhibits thymidylate synthase to disrupt DNA synthesis, leucovorin enhances 5-FU activity by stabilizing its binding to the enzyme, and oxaliplatin is a platinum agent that forms DNA crosslinks. The '1d' designation likely refers to a specific dosing schedule variant of the standard FOLFOX regimen.
Approved indications
- Colorectal cancer (likely primary indication based on FOLFOX standard use)
Common side effects
- Neutropenia
- Nausea and vomiting
- Diarrhea
- Peripheral neuropathy
- Anemia
- Mucositis
Key clinical trials
- BBO-11818 in Adult Subjects With KRAS Mutant Cancer (PHASE1)
- A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation (PHASE1)
- Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers (PHASE2)
- A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors (PHASE1)
- Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin (PHASE1)
- HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FOLFOX 1d CI brief — competitive landscape report
- FOLFOX 1d updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI